Plozalizumab (INN; hu1D9) is a humanized monoclonal antibody designed for the treatment of diabetic nephropathy and arteriovenous graft patency.[1][2]

This drug was developed by Takeda Pharmaceuticals International Co.

References

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Plozalizumab, American Medical Association.
  2. ^ World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 113" (PDF). WHO Drug Information. 29 (2).
Allikas: https://en.wikipedia.org/wiki/Plozalizumab
No tags for this post.